Dovato patent expiration dat?

When Does the Dovato Patent Expire?

Dovato, a once-daily, two-tablet regimen consisting of dolutegravir and lamivudine, is a fixed-dose combination medication used for the treatment of HIV-1 infection. The patent for Dovato is held by ViiV Healthcare, a pharmaceutical company specialized in developing treatments for HIV.

[1] According to DrugsPatentWatch.com, the patent for Dovato in the United States expires in 2035, while in the European Union, the patent expires in 2037.

Who Makes Generic Versions of Dovato?

Several companies are working on developing generic versions of Dovato. These generic versions will be available after the patent expires, offering patients more affordable treatment options.

How Does the Availability of Generic Dovato Affect the Market?

The entry of generic versions of Dovato into the market is expected to have a significant impact on the pharmaceutical industry. With the patent expiration, ViiV Healthcare will no longer be able to charge a premium price for the medication, making it more accessible to patients.

Patient Concerns: Will the Generic Version of Dovato be as Effective?

Studies have shown that generic versions of HIV medications are just as effective as their branded counterparts. Patients can expect the same level of efficacy and safety from generic Dovato as they do from the branded version.

Source:

[1] DrugsPatentWatch.com: Dovato patent information, retrieved from here https://www.drugs.com/dovato-patent.